Our molecular studies indicated that shisa3 interacts with FGFR1/FGFR3 to decrease the activation of these two receptors and their downstream AKT/mTOR pathway, resulting in restoration of EGFR-TKI sensitivity and suppression of CSC properties in lung adenocarcinoma. This evidence concerns the gene FGFR3 and lung adenocarcinoma.